# US 2006/0189687 A1 · S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0189687 A1
- Document ID: US20060189687A1
- Status: Published application
- Kind: A1
- Application number: 11/349,043
- Filed: 2006-02-06
- Published: 2006-08-24
- Earliest claimed: 2002-01-07
- Assignees: The Texas A&M University System; Board of Regents, The University of Texas System
- Inventors: Ralph Zingaro; Emil Freireich; Hatice Duzkale; Hagop Kantarjian; Srdan Verstovsek; Merida Sotelo-Lerma
- Web page: https://patentgrep.com/patent/US20060189687A1

## CPC

- C07F 9/72: Aliphatic compounds
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.

## Claims

### Claim at position 1

-21. (canceled)

### Claim 22

A method for treating cancer, comprising orally administering an organic arsenic compound, wherein the organic arsenic compound is administered at a dose greater than 10 mg/kg.

### Claim 23 (depends on 22)

A method of claim 22, wherein the organic arsenic compound has a structure
wherein
R1 and R2 are independently alkyls with 1-10 carbon atoms;
X is S or Se;
R3 is —H, —COOH, —CH2—COOH, —CH2—CH2—COOH, —CH(CH3)—COOH, —CH(CH2—CH3)—COOH, or —CH2—CH2—CH2—COOH;
n is 0 or 1;
R4 is —OH, —H, —CH3, or a glutamine substituent; or
or R3 and R4 form an unsubstituted or substituted aromatic ring with C1 and C2; and
R5 is —OH or a glycine substituent;
or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 23)

A method of claim 23, wherein R5 is —OH.

### Claim 25 (depends on 23)

A method of claim 23, wherein R3 and R4 form an unsubstituted or substituted aromatic ring with C, and C2.

### Claim 26 (depends on 23)

A method of claim 23, wherein X is S.

### Claim 27 (depends on 23)

A method of claim 23, wherein R1 and R2 are both methyl.

### Claim 28 (depends on 23)

A method of claim 23, wherein R5 is a glycine substituent.

### Claim 29 (depends on 23)

A method of claim 23, wherein R4 is —OH, —H, or —CH3.

### Claim 30 (depends on 23)

A method of claim 23, wherein the compound is complexed with pyridine hydrochloride.

### Claim 31 (depends on 23)

A method of claim 23, wherein the compound has a formula

### Claim 32 (depends on 23)

A method of claim 23, wherein the compound has a formula

### Claim 33 (depends on 23)

A method of claim 23, wherein the compound has a formula

### Claim 34 (depends on 33)

A method of claim 33, wherein the compound is provided as a formulation further comprising a pharmaceutical carrier, wherein the formulation has a pH of 5 to 7.

### Claim 35 (depends on 22)

A method of claim 22, wherein the organic arsenic compound is administered at a dose greater than 200 mg/kg.

### Claim 36

A pharmaceutical composition of an organic arsenic compound, wherein a dose of the composition comprises at least 200 mg/kg of the organic arsenic compound.

### Claim 37 (depends on 22)

A method of claim 22, wherein the cancer is selected from brain, lung, liver, spleen, kidney, lymph node, small intestine, pancreas, blood cells, bone, colon, stomach, breast, endometrium, prostate, testicle, ovary, central nervous system, skin, head and neck, esophagus, and bone marrow cancer.

### Claim 38 (depends on 37)

A method of claim 37, wherein the cancer is a hematological cancer.

### Claim 39 (depends on 38)

A method of claim 38, wherein the cancer is selected from leukemia, lymphoma, multiple myeloma, myelodysplasia, myeloproliferative disease, and refractory anemia.

### Claim 40 (depends on 39)

A method of claim 39, wherein the cancer is acute promyelocytic leukemia.

### Claim 41 (depends on 22)

A method of claim 22, wherein the organic arsenic is administered with one or more other agents or therapies.
